evocatal And EUCODIS Bioscience Enter Into Collaboration Agreement

on .

Vienna and Duesseldorf, October 5, 2010 – Industrial biotech companies EUCODIS Bioscience and evocatal today announced the formation of an alliance to jointly market the companies’ industrial enzyme products, including alcohol dehydrogenases, lipases, and other enzymes.

The two companies will leverage their knowledge of customers’ needs in their respective markets as well as their complementary resources to provide existing and future customers with a broader choice of novel enzymes and related services.

Both parties have already started to align their marketing and sales activities, including their product catalogs, and are representing and marketing each partner’s products at industry trade fairs, beginning with CPhI 2010, Paris, and Biotechnica 2010, Hannover.

Financial terms of the agreement are not being disclosed.

“We are excited about the potential of our alliance with evocatal, who combine an impressive entrepreneurial spirit with a deep understanding of developing innovative enzymes for the fine chemicals industry”, said Thomas Fischer, CEO, EUCODIS Bioscience.

Dr. Thorsten Eggert, CEO of evocatal, agreed: “We also see Eucodis as a strong, technology-driven company with a solid portfolio of branded products. By forming this partnership we truly join our forces allowing the partners to significantly broaden their offerings to existing and to new customers”.

Dr. Michael Puls, CMO of evocatal, commented on the alliance: “We really team up in this process to significantly increase our customers’ benefit. Customers have now access to a larger enzyme portfolio through a single channel and also to a much broader service network.”

“We can thus provide more expertise in biocatalysis,” added Dr. Bhupinder Hundle, Senior VP Marketing and Sales, EUCODIS Bioscience. “This supports both of us in our continuous striving to provide the best possible service.”

evocatal and EUCODIS Bioscience jointly look forward to a great teamwork and fruitful cooperation to serve their customers’ needs.


About EUCODIS Bioscience

EUCODIS Bioscience provides enzymes to the chemical, health care, and other industries, and offers custom-engineering and custom-manufacturing services.

Customers use EUCODIS Bioscience’ enzymes and services to make their manufacturing processes more efficient and cleaner and to introduce products with superior properties. The Company’s technology of in vivo-recombination is a proven tool for the directed evolution of enzymes that perform to customers’ specific requirements.

Enzymes are proteins that catalyze highly specific chemical reactions, offering a safer, cleaner, and competitive alternative to traditional chemistry. They are at the center of industrial, or “white” biotechnology, a fast growing industry segment with sales in excess of EUR100 billion.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with a subsidiary in Germany.

For more information, please visit www.eucodisbioscience.com

 

About evocatal

evocatal GmbH is a Germany-based industrial biotech company, specialized in the development of biocatalysts and enzyme-based chemical processes.

The name evocatal connects the terms ‘evolution’ and ‘catalysis’ and stands for the core competencies of the Company: the tailor-made development of new enzymes for use in the production of complex low-molecular weight compounds and fine chemicals for the pharmaceutical industry.

evocatal has built up a portfolio of proprietary biocatalysts (evozymes®) that is continuously broadened by innovative new developments meeting the demands in industry. The company furthermore offers the development of enzymes and enzyme production systems as contract service.

Furthermore evocatal has commercialized the first fluorescent protein for anaerobic applications in biomedical research and development.

For more information, please visit www.evocatal.com

 

Company contact EUCODIS Bioscience:

Thomas Fischer, MBA
CEO
EUCODIS Bioscience
Campus Vienna Biocenter II
Viehmarktgasse 2 a/ 2 OG
A-1030 Vienna
AUSTRIA
+ 43-1-8900804
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media contact EUCODIS Bioscience:

Frank Butschbacher
Investor Relations & Communications
www.butschbacher.net
+43-650-7844940
This email address is being protected from spambots. You need JavaScript enabled to view it.

Company contact evocatal:

Dr. Thorsten Eggert
CEO
evocatal GmbH
Merowingerplatz 1a
40225 Duesseldorf
GERMANY
+49-211-1576095-0

This email address is being protected from spambots. You need JavaScript enabled to view it.

Collaboration with Martin-Luther-University, Halle, Germany

on .

Vienna, Europe, April 27, 2010 – EUCODIS Bioscience, a developer and manufacturer of customized enzymes, and Martin-Luther-University Halle-Wittenberg, Germany, (MLU), today announced a collaboration agreement for the characterization of novel lipases, phospholipases, and other enzymes that EUCODIS Bioscience is marketing or has under development.

“Given the breadth of potential uses of our enzymes, we would like to provide our customers with comprehensive analytical data on the characteristics of each enzyme in a corresponding range of environments”, said Thomas Fischer, CEO of EUCODIS Bioscience, commenting on the collaboration.

“We are extremely pleased that the collaboration with MLU gives us access to the extensive scientific experience and state-of-the-art instrumentation in enzyme research and protein analysis that Professor Bordusa and his team have built at the Institute of Biochemistry and Biotechnology. The Institute will serve as a ‘center of excellence” for the extensive characterization of our enzymes, and the data generated will be of substantial value to our customers in the short term.”

“We are excited about the opportunity to collaborate with EUCODIS Bioscience as an industry partner”, said Prof. Frank Bordusa, Head of the Department Natural Materials Biochemistry of the Institute of Biochemistry and Biotechnology, Martin-Luther-University Halle-Wittenberg, Germany. “Lipases are the most versatile class of commercial enzymes. A thorough characterization of these enzyme in relation to a diverse range of potential substrates and processes is important to industrial users, and scientifically challenging. Our collaboration with an industrial enzyme developer also has the potential to generate further projects of commercial value.”

Industrial enzymes are used in extremely diverse applications. Lipases are part of the formulations of laundry detergents, moisturizing cosmetics, bakery mixes, or animal feeds, and enable industrial processes such as the extraction and processing of vegetable oils, or the production of fine chemicals from biomass in a biorefinery, among many other applications.

About MLU’s Institute of Biochemistry and Biotechnology

The Institute of Biochemistry and Biotechnology of the Martin-Luther-University Halle-Wittenberg is one of the most successful institutes of the university in terms of the recruitment of third-party funds. Currently, research covered by third-party funds includes several Collaborative and Interdisciplinary Research Centers, DFG research groups and activities within several DFG Priority Programs, as well as the application-oriented ProNet-T3 network, which has recently been funded with EUR 11 million by the German Ministry of Science and Education.

The Department Natural Materials Biochemistry is involved in a number of the aforementioned activities and has long-term experience in the use of hydrolases as biocatalysts for chemical applications. The main field of interest covers the optimization of these enzymes by rational and evolutionary protein engineering including the identification of new enzymes for semisynthesis.

For details on MLU’s Institute of Biochemistry and Biotechnology please visit http://www.biochemtech.uni-halle.de/

About EUCODIS Bioscience

EUCODIS Bioscience develops and customizes enzymes for the chemical, health care, and other industries.

Customers use EUCODIS Bioscience’ enzymes to make their manufacturing processes more efficient and cleaner, and to introduce products with superior properties. The Company’s technology of in vivo-recombination is a proven tool for the development of enzymes that perform to customers’ specific requirements.

Enzymes are biological catalysts. They are at the center of industrial, or “white” biotechnology, a fast growing industry segment with sales in excess of EUR100 billion.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with a subsidiary in Germany.

For more information, please visit www.eucodisbioscience.com

Company contact EUCODIS Bioscience:

Thomas Fischer, MBA

CEO
EUCODIS Bioscience

Campus Vienna Biocenter II
Viehmarktgasse 2 a/ 2 OG
A-1030 Vienna
AUSTRIA

+ 43-1-8900804

This email address is being protected from spambots. You need JavaScript enabled to view it.

Media contact EUCODIS Bioscience:

Frank Butschbacher

Investor Relations & Communications

www.butschbacher.net

+43-650-7844940

This email address is being protected from spambots. You need JavaScript enabled to view it.

Launch of Phospholipases Expands Enzyme Portfolio

on .

Vienna, Europe, March 9, 2010 – EUCODIS Bioscience, a company providing customized enzymes to the pharmaceutical, chemical, and other industries, announced today that it has launched a panel of phospholipases, adding a new enzyme family to its product portfolio.

Phospholipases are a group of enzymes that are widely used in the industrial processing of natural fats and oils, such as in the food and beverage industries, in the cosmetics industry, and in the manufacturing of bioproducts from renewable resources (biomass). The market for phospholipases is estimated at EUR 40 million.

In 2009, EUCODIS Bioscience has launched several enzyme products, including a library of currently 20 novel lipases and beta-lactamases

Commenting on the launch of a new product group, Thomas Fischer, CEO of EUCODIS Bioscience, said: “In adding new enzymes to our product portfolio, we continue to execute our customer-focused strategy: We offer novel enzymes with promising properties to a broad range of industries, we manufacture commercial quantities according to market demand, and we engineer enzymes to customers’ specific needs. Feedback from the market is an impressive confirmation of this strategy, with our order book filling steadily“.


About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, customizes, manufactures, and markets industrial enzymes.

EUCODIS Bioscience’ products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

The Company offers a broad portfolio of novel enzymes, including lipases, phospholipases, and beta-lactamases.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with a subsidiary in Germany.

For more information, please visit www.eucodisbioscience.com

Company contact EUCODIS Bioscience:

Thomas Fischer, MBA
CEO
EUCODIS Bioscience
Campus Vienna Biocenter II
Viehmarktgasse 2 a/ 2 OG
A-1030 Vienna

AUSTRIA
+43 1 8900804


Media contact EUCODIS Bioscience:

Frank Butschbacher
Investor Relations & Communications
www.butschbacher.net
+43 650 7844940